Table 1 Baseline characteristics of the RTX-treated SLE and AAV patients

Clinical features

 Females (n, (%))

60 (90.9)

12 (54.5)

 Age (median (IQR))

36.3 (29.8–50.3)

62.0 (44.0–70.5)

 Disease duration (median (IQR))

7.9 (2.6–14.3)

1.5 (0–6.5)

Disease activity

 SLEDAI-2K^a (n = 65) (median (IQR))

12.0 (7.0–16.0)

–

 BVAS (n = 17) (median (IQR))

–

15.0 (10.5–22.5)

Rituximab treatment regimens

 375 mg/m² × 4 weekly infusions (n, %)

38 (57.6)

5 (22.7)

 1 g 2 weeks apart (n, %)

24 (36.4)

13 (59.1)

 500 mg 2 weeks apart (n, %)

4 (6.1)

3 (13.6)

Concomitant treatments

 IV cyclophosphamide (n, %)

36 (54.5)

10 (45.4)

 IV 6-methylprednisolone (n, %)

37 (56.1)

4 (18.2)